Search

Your search keyword '"Reynolds, Kerry L."' showing total 418 results
Start Over Author "Reynolds, Kerry L."
418 results on '"Reynolds, Kerry L."'

1. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

Author

Thomas, Molly Fisher, Slowikowski, Kamil, Manakongtreecheep, Kasidet, Sen, Pritha, Samanta, Nandini, Tantivit, Jessica, Nasrallah, Mazen, Zubiri, Leyre, Smith, Neal P., Tirard, Alice, Ramesh, Swetha, Arnold, Benjamin Y., Nieman, Linda T., Chen, Jonathan H., Eisenhaure, Thomas, Pelka, Karin, Song, Yuhui, Xu, Katherine H., Jorgji, Vjola, Pinto, Christopher J., Sharova, Tatyana, Glasser, Rachel, Chan, PuiYee, Sullivan, Ryan J., Khalili, Hamed, Juric, Dejan, Boland, Genevieve M., Dougan, Michael, Hacohen, Nir, Li, Bo, Reynolds, Kerry L., and Villani, Alexandra-Chloé

Published
2024
Full Text
View/download PDF

4. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study

Author

Wan, Guihong, Chen, Wenxin, Khattab, Sara, Roster, Katie, Nguyen, Nga, Yan, Boshen, Rajeh, Ahmad, Seo, Jayhyun, Rashdan, Hannah, Zubiri, Leyre, Hadfield, Matthew J, Demehri, Shadmehr, Yu, Kun-Hsing, Lotter, William, Gusev, Alexander, LeBoeuf, Nicole R, Reynolds, Kerry L, Kwatra, Shawn G, and Semenov, Yevgeniy R

Published
2024
Full Text
View/download PDF

7. Acute kidney injury in patients treated with immune checkpoint inhibitors

Author

Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, De Seigneux, Sophie, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Mothi, Suraj Sarvode, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, Salem, Joe-Elie, Bagnis, Corinne Isnard, Rahma, Osama E, Mothi, Suraj S, Selamet, Umut, Chang, Weiting, Hirsch, Jamie S, Sakhiya, Vipulbhai, Stalbow, Daniel, Wu, Sylvia, Cennamo, Armando, Papa, Sophie, Rigg, Anne, Shaunak, Nisha, Kibbelaar, Zoe A, and Benesova, Karolina

Subjects
Kidney Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Renal and urogenital, Good Health and Well Being, Acute Kidney Injury, Aged, Cohort Studies, Female, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Male, Middle Aged, Risk Factors, immunotherapy, CTLA-4 antigen, programmed cell death 1 receptor, ICPi-AKI Consortium Investigators
Abstract

BackgroundImmune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.MethodsWe collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI.ResultsICPi-AKI occurred at a median of 16 weeks (IQR 8-32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3-10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI.ConclusionsPatients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.

Published
2021

8. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.

Author

Thavendiranathan, Paaladinesh, Zhang, Lili, Zafar, Amna, Drobni, Zsofia D, Mahmood, Syed S, Cabral, Marcella, Awadalla, Magid, Nohria, Anju, Zlotoff, Daniel A, Thuny, Franck, Heinzerling, Lucie M, Barac, Ana, Sullivan, Ryan J, Chen, Carol L, Gupta, Dipti, Kirchberger, Michael C, Hartmann, Sarah E, Weinsaft, Jonathan W, Gilman, Hannah K, Rizvi, Muhammad A, Kovacina, Bojan, Michel, Caroline, Sahni, Gagan, González-Mansilla, Ana, Calles, Antonio, Fernández-Avilés, Francisco, Mahmoudi, Michael, Reynolds, Kerry L, Ganatra, Sarju, Gavira, Juan José, González, Nahikari Salterain, García de Yébenes Castro, Manuel, Kwong, Raymond Y, Jerosch-Herold, Michael, Coelho-Filho, Otavio R, Afilalo, Jonathan, Zataraín-Nicolás, Eduardo, Baksi, A John, Wintersperger, Bernd J, Calvillo-Arguelles, Oscar, Ederhy, Stephane, Yang, Eric H, Lyon, Alexander R, Fradley, Michael G, and Neilan, Tomas G

Abstract

Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited.This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis.In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block.Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 ± 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction

Published
2021

9. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis.

Author

Zlotoff, Daniel A, Hassan, Malek Z O, Zafar, Amna, Alvi, Raza M, Awadalla, Magid, Mahmood, Syed S, Zhang, Lili, Chen, Carol L, Ederhy, Stephane, Barac, Ana, Banerji, Dahlia, Jones-O'Connor, Maeve, Murphy, Sean P, Armanious, Merna, Forrestal, Brian J, Kirchberger, Michael C, Coelho-Filho, Otavio R, Rizvi, Muhammad A, Sahni, Gagan, Mandawat, Anant, Tocchetti, Carlo G, Hartmann, Sarah, Gilman, Hannah K, Zatarain-Nicolás, Eduardo, Mahmoudi, Michael, Gupta, Dipti, Sullivan, Ryan, Ganatra, Sarju, Yang, Eric H, Heinzerling, Lucie M, Thuny, Franck, Zubiri, Leyre, Reynolds, Kerry L, Cohen, Justine V, Lyon, Alexander R, Groarke, John, Thavendiranathan, Paaladinesh, Nohria, Anju, Fradley, Michael G, and Neilan, Tomas G

Abstract

Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other cardiac conditions; however, there are no data on their utility in ICI myocarditis.From an international registry, ECG parameters were compared between 140 myocarditis cases and 179 controls across multiple time points (pre-ICI, on ICI prior to myocarditis, and at the time of myocarditis). The association between ECG values and major adverse cardiac events (MACE) was also tested.Both the QRS duration and QTc interval were similar between cases and controls prior to myocarditis. When compared with controls on an ICI (93±19 ms) or to baseline prior to myocarditis (97±19 ms), the QRS duration prolonged with myocarditis (110±22 ms, p

Published
2021

10. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor�Associated Myocarditis

Author

Zhang, Lili, Zlotoff, Daniel A, Awadalla, Magid, Mahmood, Syed S, Nohria, Anju, Hassan, Malek Z.O., Thuny, Franck, Zubiri, Leyre, Chen, Carol L, Sullivan, Ryan J, Alvi, Raza M, Rokicki, Adam, Murphy, Sean P, Jones-O’Connor, Maeve, Heinzerling, Lucie M, Barac, Ana, Forrestal, Brian J, Yang, Eric H, Gupta, Dipti, Kirchberger, Michael C, Shah, Sachin P, Rizvi, Muhammad A, Sahni, Gagan, Mandawat, Anant, Mahmoudi, Michael, Ganatra, Sarju, Ederhy, Stephane, Zatarain-Nicolas, Eduardo, Groarke, John D, Tocchetti, Carlo G, Lyon, Alexander R, Thavendiranathan, Paaladinesh, Cohen, Justine V, Reynolds, Kerry L, Fradley, Michael G, and Neilan, Tomas G

Published
2020

11. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

Author

Zhang, Lili, Awadalla, Magid, Mahmood, Syed S, Nohria, Anju, Hassan, Malek Z O, Thuny, Franck, Zlotoff, Daniel A, Murphy, Sean P, Stone, James R, Golden, Doll Lauren Alexandra, Alvi, Raza M, Rokicki, Adam, Jones-O'Connor, Maeve, Cohen, Justine V, Heinzerling, Lucie M, Mulligan, Connor, Armanious, Merna, Barac, Ana, Forrestal, Brian J, Sullivan, Ryan J, Kwong, Raymond Y, Yang, Eric H, Damrongwatanasuk, Rongras, Chen, Carol L, Gupta, Dipti, Kirchberger, Michael C, Moslehi, Javid J, Coelho-Filho, Otavio R, Ganatra, Sarju, Rizvi, Muhammad A, Sahni, Gagan, Tocchetti, Carlo G, Mercurio, Valentina, Mahmoudi, Michael, Lawrence, Donald P, Reynolds, Kerry L, Weinsaft, Jonathan W, Baksi, A John, Ederhy, Stephane, Groarke, John D, Lyon, Alexander R, Fradley, Michael G, Thavendiranathan, Paaladinesh, and Neilan, Tomas G

Abstract

Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented.From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.

Published
2020

12. Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy

Author

Lee, Charlotte, Drobni, Zsofia D., Zafar, Amna, Gongora, Carlos A., Zlotoff, Daniel A., Alvi, Raza M., Taron, Jana, Rambarat, Paula K., Schoenfeld, Sara, Mosarla, Ramya C., Raghu, Vineet K., Hartmann, Sarah E., Gilman, Hannah K., Murphy, Sean P., Sullivan, Ryan J., Faje, Alexander, Hoffmann, Udo, Zhang, Lili, Mayrhofer, Thomas, Reynolds, Kerry L., and Neilan, Tomas G.

Published
2022
Full Text
View/download PDF

13. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

Author

Quinaglia, Thiago, Gongora, Carlos, Awadalla, Magid, Hassan, Malek Z.O., Zafar, Amna, Drobni, Zsofia D., Mahmood, Syed S., Zhang, Lili, Coelho-Filho, Otavio R., Suero-Abreu, Giselle A., Rizvi, Muhammad A., Sahni, Gagan, Mandawat, Anant, Zatarain-Nicolás, Eduardo, Mahmoudi, Michael, Sullivan, Ryan, Ganatra, Sarju, Heinzerling, Lucie M., Thuny, Franck, Ederhy, Stephane, Gilman, Hannah K., Sama, Supraja, Nikolaidou, Sofia, Mansilla, Ana González, Calles, Antonio, Cabral, Marcella, Fernández-Avilés, Francisco, Gavira, Juan José, González, Nahikari Salterain, García de Yébenes Castro, Manuel, Barac, Ana, Afilalo, Jonathan, Zlotoff, Daniel A., Zubiri, Leyre, Reynolds, Kerry L., Devereux, Richard, Hung, Judy, Picard, Michael H., Yang, Eric H., Gupta, Dipti, Michel, Caroline, Lyon, Alexander R., Chen, Carol L., Nohria, Anju, Fradley, Michael G., Thavendiranathan, Paaladinesh, and Neilan, Tomas G.

Published
2022
Full Text
View/download PDF

14. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

Author

Le, Thomas K., Brown, Isabelle, Goldberg, Rebecca, Taylor, Matthew T., Deng, Junwen, Parthasarathy, Varsha, Bordeaux, Zachary A., Alphonse, Martin Prince, Kwatra, Madan M., Naranbhai, Vivek, Gusev, Alexander, Alhariri, Jihad, LeBoeuf, Nicole R., Reynolds, Kerry L., Cappelli, Laura C., Naidoo, Jarushka, Brahmer, Julie R., Kang, Sewon, Semenov, Yevgeniy R., and Kwatra, Shawn G.

Published
2022
Full Text
View/download PDF

15. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

Author

Leaf, Rebecca Karp, Ferreri, Christopher, Rangachari, Deepa, Mier, James, Witteles, Wesley, Ansstas, George, Anagnostou, Theodora, Zubiri, Leyre, Piotrowska, Zofia, Oo, Thein H, Iberri, David, Yarchoan, Mark, Salama, April KS, Johnson, Douglas B, Leavitt, Andrew D, Rahma, Osama E, Reynolds, Kerry L, and Leaf, David E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Rare Diseases, Hematology, Autoimmune Disease, Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Hemolytic, Autoimmune, Female, Glucocorticoids, Hemoglobins, Humans, Immunosuppression Therapy, Male, Middle Aged, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi-AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22-110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2-12.9 g/dL) and 6.3 g/dL (IQR, 6.1-8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were rechallenged with ICPis, and one (14%) developed recurrent AIHA. Clinical and laboratory features of ICPi-AIHA were similar in DAT positive and negative patients. ICPi-AIHA shares many clinical features with primary AIHA; however, a unique aspect of ICPi-AIHA is a high incidence of DAT negativity. Glucocorticoids are an effective first-line treatment in the majority of patients with ICPi-AIHA, and most patients who are rechallenged with an ICPi do not appear to develop recurrence of AIHA.

Published
2019

16. Identification of Immune Checkpoint Inhibitor–Induced Diabetes.

Author

Ruiz-Esteves, Karina N., Shank, Kaitlyn R., Deutsch, Aaron J., Gunturi, Alekhya, Chamorro-Pareja, Natalia, Colling, Caitlin A., Zubiri, Leyre, Perlman, Katherine, Ouyang, Tianqi, Villani, Alexandra-Chloé, Florez, Jose C., Gusev, Alexander, Reynolds, Kerry L., Miller, Karen K., Udler, Miriam S., Sise, Meghan E., and Rengarajan, Michelle

Published
2024
Full Text
View/download PDF

18. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Author

Chen, Steven T, primary, Semenov, Yevgeniy R, additional, Alloo, Allireza, additional, Bach, Daniel Q, additional, Betof Warner, Allison, additional, Bougrine, Amina, additional, Burton, Leeann, additional, Cappelli, Laura C, additional, Castells, Mariana, additional, Cohen, Justine, additional, Dewan, Anna K, additional, Fadden, Riley, additional, Guggina, Lauren, additional, Hegde, Aparna, additional, Huang, Victor, additional, Johnson, Douglas B, additional, Kaffenberger, Benjamin, additional, Kroshinsky, Daniela, additional, Kwatra, Shawn, additional, Kwong, Bernice, additional, Lacouture, Mario E, additional, Larocca, Cecilia, additional, Leventhal, Jonathan, additional, Markova, Alina, additional, McDunn, Jon, additional, Mooradian, Meghan J, additional, Naidoo, Jarushka, additional, Choi, Jennifer, additional, Nambudiri, Vinod, additional, Nelson, Caroline A, additional, Patel, Anisha B, additional, Pimkina, Julia, additional, Rine, Johnathan, additional, Rubin, Krista M, additional, Sauder, Maxwell, additional, Shaigany, Sheila, additional, Shariff, Afreen, additional, Sullivan, Ryan J, additional, Zubiri, Leyre, additional, Reynolds, Kerry L, additional, and LeBoeuf, Nicole R, additional

Published
2024
Full Text
View/download PDF

19. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study

Author

Gupta, Shruti, primary, Glezerman, Ilya G, additional, Hirsch, Jamie S, additional, Chen, Kevin L, additional, Devaraj, Nishant, additional, Wells, Sophia L, additional, Seitter, Robert H, additional, Kaunfer, Sarah A, additional, Jose, Arunima M, additional, Rao, Shreya P, additional, Ortega, Jessica L, additional, Green-Lingren, Olivia, additional, Hayden, Robert, additional, Bendapudi, Pavan K, additional, Chute, Donald F, additional, Sise, Meghan E, additional, Jhaveri, Kenar D, additional, Page, Valda D, additional, Abramson, Matthew H, additional, Motwani, Shveta S, additional, Xu, Wenxin, additional, Sehgal, Kartik, additional, Reynolds, Kerry L, additional, Bansal, Anip, additional, Abudayyeh, Ala, additional, and Leaf, David E, additional

Published
2024
Full Text
View/download PDF

20. Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study

Author

Reardon, Rachel M., primary, Perlman, Katherine L., additional, Asdourian, Maria S., additional, Shah, Nishi, additional, Jacoby, Ted V., additional, Thompson, Leah L., additional, Reynolds, Kerry L., additional, Semenov, Yevgeniy R., additional, and Chen, Steven T., additional

Published
2024
Full Text
View/download PDF

31. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study

Author

Wan, Guihong, primary, Nguyen, Nga, additional, Leung, Bonnie W., additional, Rashdan, Hannah, additional, Tang, Kimberly, additional, Roster, Katie, additional, Collier, Michael R., additional, Ugwu-Dike, Pearl O., additional, Raval, Neel S., additional, Alexander, Nora A., additional, Jairath, Ruple, additional, Phillipps, Jordan, additional, Amadife, Munachimso, additional, Zhang, Shijia, additional, Gusev, Alexander, additional, Chen, Steven T., additional, Reynolds, Kerry L., additional, LeBoeuf, Nicole R., additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

32. Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor

Author

Blum, Steven M., primary, Zlotoff, Daniel A., additional, Smith, Neal P., additional, Kernin, Isabela J., additional, Ramesh, Swetha, additional, Zubiri, Leyre, additional, Caplin, Joshua, additional, Tirard, Alice, additional, Sen, Prith, additional, Song, Yuhui, additional, Barth, Jaimie L., additional, Slowikowski, Kamil, additional, Nasrallah, Mazen, additional, Tantivit, Jessica, additional, Manakongtreecheep, Kasidet, additional, Arnold, Benjamin Y., additional, McGuire, John, additional, Pinto, Christopher J., additional, McLoughlin, Daniel, additional, Jackson, Monica, additional, Chan, PuiYee, additional, Lawless, Aleigha, additional, Sharova, Tatyana, additional, Nieman, Linda T., additional, Gainor, Justin F., additional, Juric, Dejan, additional, Mino-Kenudsen, Mari, additional, Sullivan, Ryan J., additional, Boland, Genevieve M., additional, Stone, James R., additional, Thomas, Molly F., additional, Neilan, Tomas G., additional, Reynolds, Kerry L., additional, and Villani, Alexandra-Chloe, additional

Published
2023
Full Text
View/download PDF

33. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study

Author

Wan, Guihong C., primary, Nguyen, Nga, additional, Leung, Bonnie W., additional, Rashdan, Hannah, additional, Tang, Kimberly, additional, Roster, Katie, additional, Collier, Michael R., additional, Ugwu-Dike, Pearl O., additional, Raval, Neel S., additional, Alexander, Nora A., additional, Jairath, Ruple, additional, Phillipps, Jordan, additional, Amadife, Munachimso, additional, Zhang, Shijia, additional, Gusev, Alexander, additional, Chen, Steven T., additional, Reynolds, Kerry L., additional, LeBoeuf, Nicole R., additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

34. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Author

Mahmood, Syed S., Fradley, Michael G., Cohen, Justine V., Nohria, Anju, Reynolds, Kerry L., Heinzerling, Lucie M., Sullivan, Ryan J., Damrongwatanasuk, Rongras, Chen, Carol L., Gupta, Dipti, Kirchberger, Michael C., Awadalla, Magid, Hassan, Malek Z.O., Moslehi, Javid J., Shah, Sachin P., Ganatra, Sarju, Thavendiranathan, Paaladinesh, Lawrence, Donald P., Groarke, John D., and Neilan, Tomas G.

Published
2018
Full Text
View/download PDF

35. Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Author

Wan, Guihong, Nguyen, Nga, Leung, Bonnie W., Rashdan, Hannah, Tang, Kimberly, Roster, Katie, Collier, Michael R., Ugwu-Dike, Pearl O., Raval, Neel S., Alexander, Nora A., Jairath, Ruple, Phillipps, Jordan, Amadife, Munachimso, Zhang, Shijia, Gusev, Alexander, Chen, Steven T., Reynolds, Kerry L., LeBoeuf, Nicole R., Kwatra, Shawn G., and Semenov, Yevgeniy R.

Published
2024
Full Text
View/download PDF

36. Medication-Related Adverse Events and Discordancies in Cystatin C–Based vs Serum Creatinine–Based Estimated Glomerular Filtration Rate in Patients With Cancer

Author

Hanna, Paul E., primary, Wang, Qiyu, additional, Strohbehn, Ian A., additional, Moreno, Daiana, additional, Harden, Destiny, additional, Ouyang, Tianqi, additional, Katz-Agranov, Nurit, additional, Seethapathy, Harish, additional, Reynolds, Kerry L., additional, Gupta, Shruti, additional, Leaf, David E., additional, and Sise, Meghan E., additional

Published
2023
Full Text
View/download PDF

39. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

Author

Drobni, Zsofia D., Alvi, Raza M., Taron, Jana, Zafar, Amna, Murphy, Sean P., Rambarat, Paula K., Mosarla, Rayma C., Lee, Charlotte, Zlotoff, Daniel A., Raghu, Vineet K., Hartmann, Sarah E., Gilman, Hannah K., Gong, Jingyi, Zubiri, Leyre, Sullivan, Ryan J., Reynolds, Kerry L., Mayrhofer, Thomas, Zhang, Lili, Hoffmann, Udo, and Neilan, Tomas G

Published
2020
Full Text
View/download PDF

43. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

Author

Zhang, Lili, Zlotoff, Daniel A., Awadalla, Magid, Mahmood, Syed S., Nohria, Anju, Hassan, Malek Z.O., Thuny, Franck, Zubiri, Leyre, Chen, Carol L., Sullivan, Ryan J., Alvi, Raza M., Rokicki, Adam, Murphy, Sean P., Jones-O’Connor, Maeve, Heinzerling, Lucie M., Barac, Ana, Forrestal, Brian J., Yang, Eric H., Gupta, Dipti, Kirchberger, Michael C., Shah, Sachin P., Rizvi, Muhammad A., Sahni, Gagan, Mandawat, Anant, Mahmoudi, Michael, Ganatra, Sarju, Ederhy, Stephane, Zatarain-Nicolas, Eduardo, Groarke, John D., Tocchetti, Carlo G., Lyon, Alexander R., Thavendiranathan, Paaladinesh, Cohen, Justine V., Reynolds, Kerry L., Fradley, Michael G., and Neilan, Tomas G.

Published
2020
Full Text
View/download PDF

44. Supplementary Data from Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Author

Spring, Laura M., primary, Fell, Geoffrey, primary, Arfe, Andrea, primary, Sharma, Chandni, primary, Greenup, Rachel, primary, Reynolds, Kerry L., primary, Smith, Barbara L., primary, Alexander, Brian, primary, Moy, Beverly, primary, Isakoff, Steven J., primary, Parmigiani, Giovanni, primary, Trippa, Lorenzo, primary, and Bardia, Aditya, primary

Published
2023
Full Text
View/download PDF

45. Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

Author

Park, Benjamin C., primary, Narayanan, Sathya, additional, Gavralidis, Alexander, additional, Ye, Fei, additional, Fan, Run, additional, Sullivan, Ryan J., additional, Boland, Genevieve, additional, Reynolds, Kerry L, additional, Balko, Justin M., additional, Carlino, Matteo S., additional, Long, Georgina V., additional, Zubiri, Leyre, additional, Menzies, Alexander M., additional, and Johnson, Douglas B., additional

Published
2023
Full Text
View/download PDF

47. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy

Author

Nguyen, Nga, primary, Wan, Guihong, additional, Ugwu-Dike, Pearl, additional, Alexander, Nora A., additional, Raval, Neel, additional, Zhang, Shijia, additional, Jairath, Ruple, additional, Phillipps, Jordan, additional, Leung, Bonnie, additional, Roster, Katie, additional, Seo, Jayhyun, additional, Lu, Chenyue, additional, Tang, Kimberly, additional, Choi, Min Seok, additional, DeSimone, Mia S., additional, Theodosakis, Nicholas, additional, Amadife, Munachimso, additional, Cox, Nevada, additional, Le, Thomas K., additional, Liu, Feng, additional, Chen, Wenxin, additional, Bai, Xue, additional, Boland, Genevieve, additional, Liu, David, additional, Hurlbert, Marc S., additional, LeBoeuf, Nicole, additional, Reynolds, Kerry L., additional, Yu, Kun-Hsing, additional, Tsao, Hensin, additional, Asgari, Maryam, additional, Gusev, Alexander, additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

48. Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study

Author

Asdourian, Maria S., primary, Jacoby, Ted V., additional, Shah, Nishi, additional, Thompson, Leah L., additional, Otto, Tracey, additional, Semenov, Yevgeniy R., additional, LeBoeuf, Nicole R., additional, Reynolds, Kerry L., additional, Dewan, Anna K., additional, and Chen, Steven T., additional

Published
2023
Full Text
View/download PDF

50. Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma

Author

Stephens, Michael R., primary, Asdourian, Maria S., additional, Jacoby, Ted V., additional, Shah, Nishi, additional, Thompson, Leah L., additional, Otto, Tracey, additional, Semenov, Yevgeniy R., additional, Reynolds, Kerry L., additional, Sullivan, Ryan J., additional, Foreman, Ruth K., additional, and Chen, Steven T., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results